Topadur Pharma AG Strengthens Board with Key Appointments

Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, has announced the election of Dr. Felix R. Ehrat and Dr. Peter Jager to its Board of Directors. The appointments bring strategic and industry expertise at a pivotal time for the company, as it progresses its clinical programs. Currently, Topadur's primary project, TOP-N53, is in Phase 2a clinical trials for digital ulcers in systemic sclerosis, while TOP-M119 is being prepared for trials in alopecia.

Dr. Felix R. Ehrat, former Group General Counsel of Novartis, brings nearly four decades of experience in corporate law and M&A. His expertise in governance and capital markets enhances the board's strategic capabilities. Dr. Peter Jager, with a career spanning major global pharmaceutical roles, will contribute significantly to Topadur's commercial strategy, especially in capital markets readiness. Dr. Dominik Escher and Cornelia Gehrig did not seek re-election and were thanked for their contributions.